Abstract
Gestational diabetes mellitus (GDM) and pre-gestational diabetes are known to pose risks to the mother and developing fetus, often related to abnormal fetal growth. One potential mediator of maternal effects on fetal growth is Placental Growth Hormone (PGH). PGH is produced by the syncytiotrophoblast and found predominantly in the maternal circulation. It progressively replaces pituitary growth hormone (hGH) in the human maternal circulation from midgestation onwards, peaking towards term. PGH appears to be an important potential regulator of maternal insulin resistance in human pregnancy and may influence fetal growth both by modifying substrate availability and through paracrine actions in the placental bed. The details of PGH regulation remain relatively poorly understood, but current evidence does suggest a central role in growth restricted pregnancies. There is currently less evidence of a pathophysiologic role in production of the macrosomic fetal phenotype commonly seen in response to hyperglycaemia, although our recent in vitro studies do raise the possibility of feto-placental feedback as a mechanism of growth modulation.
Keywords: Placental growth hormone, Insulin-like Growth Factor-1, Diabetes, Pregnancy, Fetal growth, Insulin resistance
Current Diabetes Reviews
Title: Placental Growth Hormone, Fetal Growth and the IGF Axis in Normal and Diabetic Pregnancy
Volume: 5 Issue: 3
Author(s): H. D. McIntyre, W. Zeck and A. Russell
Affiliation:
Keywords: Placental growth hormone, Insulin-like Growth Factor-1, Diabetes, Pregnancy, Fetal growth, Insulin resistance
Abstract: Gestational diabetes mellitus (GDM) and pre-gestational diabetes are known to pose risks to the mother and developing fetus, often related to abnormal fetal growth. One potential mediator of maternal effects on fetal growth is Placental Growth Hormone (PGH). PGH is produced by the syncytiotrophoblast and found predominantly in the maternal circulation. It progressively replaces pituitary growth hormone (hGH) in the human maternal circulation from midgestation onwards, peaking towards term. PGH appears to be an important potential regulator of maternal insulin resistance in human pregnancy and may influence fetal growth both by modifying substrate availability and through paracrine actions in the placental bed. The details of PGH regulation remain relatively poorly understood, but current evidence does suggest a central role in growth restricted pregnancies. There is currently less evidence of a pathophysiologic role in production of the macrosomic fetal phenotype commonly seen in response to hyperglycaemia, although our recent in vitro studies do raise the possibility of feto-placental feedback as a mechanism of growth modulation.
Export Options
About this article
Cite this article as:
McIntyre D. H., Zeck W. and Russell A., Placental Growth Hormone, Fetal Growth and the IGF Axis in Normal and Diabetic Pregnancy, Current Diabetes Reviews 2009; 5 (3) . https://dx.doi.org/10.2174/157339909788920947
DOI https://dx.doi.org/10.2174/157339909788920947 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Thrombin Activatable Fibrinolysis Inhibitor in Endocrine and Cardiovascular Disorders: An Update
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Glycaemic Variability and Pancreatic ß-cell Dysfunction
Current Diabetes Reviews Erythropoietin: New Horizon in Cardiovascular Medicine
Recent Patents on Cardiovascular Drug Discovery EDITORIAL: Spicing Up the Management of Type 2 Diabetes with Cinnamon
Current Clinical Pharmacology Pulmonary Hypertension: Current Therapy and Future Prospects
Cardiovascular & Hematological Agents in Medicinal Chemistry Comparison of Salivary Antioxidants and Oxidative Stress Status in Gestational Diabetes Mellitus and Healthy Pregnant Women
Endocrine, Metabolic & Immune Disorders - Drug Targets The PD-1/PD-L1 Pathway in Human Pathology
Current Molecular Medicine Metformin Beyond Diabetes: New Life for an Old Drug
Current Diabetes Reviews Lipid Mediator Profiling in Pulmonary Disease
Current Pharmaceutical Biotechnology QSAR Studies of PTP1B Inhibitors: 1, 2-Naphthoquinone Derivatives
Letters in Drug Design & Discovery Therapeutic Potential of N-Acetylcysteine for Wound Healing, Acute Bronchiolitis, and Congenital Heart Defects
Current Drug Metabolism Do Advanced Glycation End Products (AGEs) Contribute to the Comorbidities of Polycystic Ovary Syndrome (PCOS)?
Current Pharmaceutical Design Proteomic Profiling of Maternal Serum for Early Risk Analysis of Preterm Birth
Current Proteomics PPAR- γ Agonist in Treatment of Diabetes: Cardiovascular Safety Considerations
Cardiovascular & Hematological Agents in Medicinal Chemistry Selective Divalent Copper Chelation for the Treatment of Diabetes Mellitus
Current Medicinal Chemistry Placental Drug Disposition and Its Clinical Implications
Current Drug Metabolism The Effect of Sex and Gender on Diabetic Complications
Current Diabetes Reviews The Interplay of Marine Exposure in Gestational Diabetes
Current Women`s Health Reviews Dyslipidemia and Cardiovascular Disease Prevention in South Asians: A Review and Discussion of Causes, Challenges and Management Strategies
Current Diabetes Reviews Establishing Maternal Tolerance: The Role of Regulatory T Cells (Tregs) in Pregnancy and Pathophysiology of Preeclampsia
Current Women`s Health Reviews